Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Organogenesis Holding (ORGO) Misses Q1 EPS by 6c, Revenues Beat; Offers FY19 Revenue Outlook
May 10, 2019 7:16 AM EDTOrganogenesis Holding (NASDAQ: ORGO) reported Q1 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $57.1 million versus the consensus estimate of $52.6 million.
First Quarter 2019 Financial Summary:
Net revenue of $57.1 million for the first quarter of 2019, up 60.8% compared to net revenue of $35.5 million for the first quarter of 2018. Net revenue comprised:Net revenue from Advanced Wound Care products of $47.8 million, up 63.7% from the first quarter of 2018.Net revenue from Surgical & Sports Medicine products of $9.3 million, up 47.2% from the first quarter of... More